Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
PR92246
DARMSTADT, Germany, Oct. 13, 2021 /PRNewswire=KYODO JBN/ --
- Expansion in Carlsbad, California, USA, doubles production capacity to
support commercialization and industrialization of viral vectors
- Investment serves customers in addressing larger patient populations with new
curative treatments
- Enables suspension production of viral vectors up to 1,000-liter scale
- Project adds to company's ambition to accelerate growth through investments
in "Big 3" businesses, which includes plans to expand Process Solutions'
contract manufacturing and development organization (CDMO) services for
traditional and novel modalities
Merck, a leading science and technology company, today announced the opening of
its second Carlsbad, California-based facility, significantly expanding its
global CDMO footprint. This new EUR100 million, 140,000-square foot facility
will more than double the company's existing capacity to support large-scale
commercial and industrial manufacturing for viral gene therapy, in a market
expected to grow to $10 billion by 2026.
Photo - https://mma.prnewswire.com/media/1657458/Merck_Carlsbad.jpg
"Today, most gene therapies target rare diseases, but there is an urgent need
to efficiently manufacture these treatments to reach larger patient
populations," said Matthias Heinzel, Member of the Executive Board of Merck and
CEO Life Science. "As a leader in viral vector manufacturing, this increase in
capacity and scale is the next step in enabling our customers to bring new
curative treatments to market."
This is the company's second Carlsbad, California-based facility to serve cell
and gene therapy customers driven by the industry's rapid adoption of viral
vector-based therapies. Between the two facilities, there are 30 cleanroom
suites to support all aspects of manufacturing from small- to large-scale
clinical and commercial production. The new facility leverages cutting-edge
suspension technology to enable scalable and cost-effective manufacturing.
"We are continuing to invest in solving cell and gene therapy challenges in
development and manufacturing, working alongside drug developers to
industrialize, scale and accelerate the path to deliver therapies to patients,"
Heinzel added.
The expansion of the Carlsbad facility adds to the company's ambition to
accelerate growth through investments in the "Big 3", including the Process
Solutions business unit within the Life Science business sector as a key driver.
Merck has proven its commercial execution and global regulatory success as one
of the first CDMOs to be granted U.S. Food and Drug Administration and European
Medicines Agency approval for viral vector manufacturing. With nearly 30 years
of experience in cell and gene therapy, Merck offers unique CDMO services
streamlined as a single, highly experienced provider.
All Merck Press Releases are distributed by e-mail at the same time they become
available on the Merck Website. Please go to
http://www.merckgroup.com/subscribe to register online, change your selection
or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare,
life science and electronics. Around 58,000 employees work to make a positive
difference to millions of people's lives every day by creating more joyful and
sustainable ways to live. From advancing gene editing technologies and
discovering unique ways to treat the most challenging diseases to enabling the
intelligence of devices – the company is everywhere. In 2020, Merck generated
sales of EUR17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to
Merck's technological and scientific advances. This is how Merck has thrived
since its founding in 1668. The founding family remains the majority owner of
the publicly listed company. Merck holds the global rights to the Merck name
and brand. The only exceptions are the United States and Canada, where the
business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma
in life science, and EMD Electronics.
SOURCE Merck
CONTACT: chantal.gilsdorf@merckgroup.com Phone: +49 151 1454 2860
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。